IP Library Granted Patent US 7,871,807
Granted Patent B2
US 7,871,807 · App. 12/238,740 · Granted Jan 18, 2011

Method for producing the flu virus

Assignee: Sanofi Pasteur, S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,871,807
App. No.
12/238,740
Granted
Jan 18, 2011
Kind
B2
Abstract

The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.

Claims (24)

1. A method for producing flu virus comprising:

a) immunizing a hen by administering a flu vaccine to the hen,

b) triggering embryogenesis in one or more eggs of the immunized hen,

c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs,

d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and

e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.

2. The method as claimed in claim 1 , wherein the flu vaccine comprises hemagglutinin of a flu virus in the form of protein and/or of a gene encoding this protein.

3. The method as claimed in claim 2 , wherein the flu vaccine protects the hen against avian flu.

4. The method as claimed in claim 2 , wherein the flu vaccine comprises an inactivated whole flu virus or a live attenuated flu virus.

5. The method as claimed in claim 2 , wherein the flu vaccine comprises a product derived from an inactivated whole flu virus.

6. The method as claimed in claim 2 , wherein the vaccine also comprises an adjuvant.

7. The method as claimed in claim 2 , wherein the flu vaccine comprises a vector comprising a gene encoding flu virus hemagglutinin.

8. The method as claimed in claim 7 , wherein the vector is a poxvirus.

9. The method as claimed in claim 8 , wherein the vector also comprises a gene encoding flu virus neuraminidase.

10. The method as claimed in claim 7 , wherein the vaccine also comprises an adjuvant.

11. The method as claimed in claim 2 , wherein the flu virus hemagglutinin in the form of protein and/or of a gene encoding this protein contained in the composition of the vaccine that is administered to the hens and the hemagglutinin of the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens are of different subtypes.

12. The method as claimed in claim 2 , wherein the flu virus hemagglutinin in the form of protein and/or of a gene encoding this protein contained in the composition of the vaccine that is administered to the hens and the hemagglutinin of the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens are of the same subtype.

13. The method as claimed in claim 2 , wherein the flu virus hemagglutinin in the form of protein and/or of a gene encoding this protein contained in the composition of the vaccine that is administered to the hens and the hemagglutinin of the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens are identical.

14. The method as claimed in claim 4 , wherein the flu virus contained in the composition of the vaccine that is administered to the hens is identical to the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens.

15. The method as claimed in claim 2 , wherein the flu virus hemagglutinin in the form of protein and/or of a gene encoding this protein contained in the composition of the vaccine that is administered to the hens and the hemagglutinin of the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens are independently selected from the group of hemagglutinins of the H5, H6, H7 and H9 subtypes.

16. The method as claimed in claim 15 , wherein the flu virus hemagglutinin in the form of protein and/or of a gene encoding this protein contained in the composition of the vaccine that is administered to the hens and the hemagglutinin of the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens are of the same subtype.

17. The method as claimed in claim 16 , wherein the flu virus hemagglutinin in the form of protein and/or of a gene encoding this protein contained in the composition of the vaccine that is administered to the hens and the hemagglutinin of the flu virus that is used to infect the allantoic cavity of the embryonated eggs from the immunized hens are identical.

18. The method as claimed in claim 1 , wherein the method further comprises purification of the virus.

19. The method as claimed in claim 18 , wherein the method further comprises inactivation of the virus.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: MERIAL LIMITED
To: MERIAL, INC.
Reel/Frame 049557/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: MERIAL, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 049557/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2010
From: BUBLOT, MICHEL JOSEPH MARIE; LE GROS, FRANCOIS-XAVIER
To: MERIAL LIMITED
Reel/Frame 025491/0204 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TWO ASSIGNMENTS RECORDED AS ONE BY REMOVING THE SECOND ASSIGNMENT (TO MERIAL LIMITED BY INVENTORS M. BUBLOT AND F. LEGROS) PREVIOUSLY RECORDED ON REEL 021593 FRAME 0505. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT BY INVENTORS GERDIL, MOSTE AND LEGASTELOIS TO SANOFI PASTEUR S.A.. Recorded Dec 14, 2010
From: GERDIL, CATHERINE; MOSTE, CATHERINE; LEGASTELOIS, ISABELLE
To: SANOFI PASTEUR S.A.
Reel/Frame 025497/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2008
From: GERDIL, CATHERINE; MOSTE, CATHERINE; LEGASTELOIS, ISABELLE; BUBLOT, MICHEL JOSEPH MARIE; LE GROS, FRANCOIS-XAVIER
To: SANOFI PASTEUR; MERIAL LIMITED
Reel/Frame 021593/0505 →
Priority Claims (1)
FR 07 57884 · Sep 26, 2007 · national
Continuity (2)
Provisional Application 6106365900 · Apr 2, 2008
Related Publication 20090081255A1 · Mar 26, 2009